KYTX compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

KYTXKyverna Therapeutics, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

KYTXKyverna Therapeutics, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

KYTX: latest quarter not drawable.Method ›

Price

rebased to 0%

KYTX, solidAMGN, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only KYTX 3

—Minaris Advanced Therapiesunlistedsupplier

—National Institutes of Healthunlistedsupplier

—Oxford Biomedica (UK)unlistedsupplier

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

8 more · AMGN chain ›

KYTXKyverna Therapeutics, Inc.

5.14· pre 5.20· delayed

Mkt cap$319.1MRevenue—Revenue—

AMGNAmgen Inc

478.34· pre 480.97· delayed

Pre-marketNov 5 '26delayed

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

Pre-marketNov 5 '26delayed

KYTXKyverna Therapeutics, Inc.

AMGNAmgen Inc

5.14pre 5.20delayed

Price

478.34pre 480.97delayed

$319.1M

Mkt cap

$258.8B

—

Revenue

$10.4BQ3 FY26

—

Revenue

$36.8BFY25

KYTX5.14vsAMGN478.34Pre-marketNov 5 '26delayed